486 related articles for article (PubMed ID: 21175542)
1. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
[TBL] [Abstract][Full Text] [Related]
2. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of haemodiafiltration with ultrafiltrate regeneration in the reduction of light chains in multiple myeloma with renal failure.
Pendón-Ruiz de Mier MV; Alvarez-Lara MA; Ojeda-López R; Martín-Malo A; Carracedo J; Caballero-Villarraso J; Alonso C; Aljama P
Nefrologia; 2013 Nov; 33(6):788-96. PubMed ID: 24241366
[TBL] [Abstract][Full Text] [Related]
4. Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study.
Granger Vallée A; Chenine L; Leray-Moragues H; Patrier L; Cognot C; Cartron G; Cristol JP; Canaud B
Nephrol Dial Transplant; 2011 Nov; 26(11):3627-33. PubMed ID: 21508098
[TBL] [Abstract][Full Text] [Related]
5. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
Cockwell P; Cook M
Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
[TBL] [Abstract][Full Text] [Related]
6. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.
Hutchison CA; Cockwell P; Reid S; Chandler K; Mead GP; Harrison J; Hattersley J; Evans ND; Chappell MJ; Cook M; Goehl H; Storr M; Bradwell AR
J Am Soc Nephrol; 2007 Mar; 18(3):886-95. PubMed ID: 17229909
[TBL] [Abstract][Full Text] [Related]
7. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
Hada R; Poudyal B; Sharma A; Khatri R
JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
[TBL] [Abstract][Full Text] [Related]
8. Extracorporeal treatment of cast nephropathy.
Gakhar B; Kobrin S; Berns JS
Semin Dial; 2011; 24(1):9-11. PubMed ID: 21324000
[TBL] [Abstract][Full Text] [Related]
9. Management options for cast nephropathy in multiple myeloma.
Cockwell P; Hutchison CA
Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-dexamethasone combination in a patient with refractory multiple myeloma and impaired renal function.
Nozza A; Siracusano L; Armando S
Clin Ther; 2006 Jun; 28(6):953-9. PubMed ID: 16860177
[TBL] [Abstract][Full Text] [Related]
11. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
[TBL] [Abstract][Full Text] [Related]
12. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
Sinisalo M; Silvennoinen R; Wirta O
Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
[TBL] [Abstract][Full Text] [Related]
13. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Haemodiafiltration with Heat Sterilized High-Flux Polyphenylene HF Dialyzer in Reducing Free Light Chains in Patients with Myeloma Cast Nephropathy.
Rousseau-Gagnon M; Agharazii M; De Serres SA; Desmeules S
PLoS One; 2015; 10(10):e0140463. PubMed ID: 26466100
[TBL] [Abstract][Full Text] [Related]
15. A novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR).
Pasquali S; Iannuzzella F; Corradini M; Mattei S; Bovino A; Stefani A; Palladino G; Caiazzo M
J Nephrol; 2015 Apr; 28(2):251-4. PubMed ID: 25149172
[TBL] [Abstract][Full Text] [Related]
16. Serum Free Light Chains Removal by HFR Hemodiafiltration in Patients with Multiple Myeloma and Acute Kidney Injury: a Case Series.
Menè P; Giammarioli E; Fofi C; Antolino G; Verde G; Tafuri A; Punzo G; Festuccia F
Kidney Blood Press Res; 2018; 43(4):1263-1272. PubMed ID: 30078004
[TBL] [Abstract][Full Text] [Related]
17. Myeloma kidney: improving clinical outcomes?
Haynes R; Leung N; Kyle R; Winearls CG
Adv Chronic Kidney Dis; 2012 Sep; 19(5):342-51. PubMed ID: 22920645
[TBL] [Abstract][Full Text] [Related]
18. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
19. Rapid reduction of extremely high kappa free light chains in a patient with myeloma cast nephropathy.
Snozek CLH; Kinard TN; Adamski J
J Clin Apher; 2018 Jun; 33(3):439-443. PubMed ID: 29427353
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study.
Sens F; Chaintreuil D; Jolivot A; Guebre-Egziabher F; Robinson P; Karlin L; Bridoux F; Juillard L
Am J Nephrol; 2017; 46(5):355-363. PubMed ID: 29017155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
